Aptamer for target delivery

2-2_edited.jpg
No.
Principle Investigator(s)
Title
Funding Body
1
Prof. Ge Zhang
Role of osteoclast-derived exosomal miR-214 in regulating osteoblastic bone formation (2017.1.1-2019.12.31 , HK$1334,644)
GRF/RGC
2
Prof. Ge Zhang
The role of osteoclastic miR-214-3p in early osteoarthritis development (2018.1.1-2020.6.30, HK$871,855)
GRF/RGC
3
Prof. Ge Zhang
Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipid nanoparticles for therapeutic genome editing of miR-214 in osteosarcoma (2018.3.1-2020.2.28, HK$2,993,400)
HKBU-RC
4
Dr. Baosheng Guo
Understanding mechanical stimulation-independent effects of skeletal muscle on bone: role of muscle-derived miRNA in regulating osteoblastic bone formation (2017.01.01-2018.12.31, HKD653,436)
GRF/RGC
5
Dr. Baosheng Guo
A delivery system specifically targeting osteoclasts for encapsulating osteoclastic miRNAs modulator to inhibit bone resorption ( 2016.1.1-2019.12.31, RMB600,000)
NSFC
6
Dr. Defang Li
The effect of miR-214-3p on osteolytic bone metastasis of breast cancer by regulating osteoclast differentiation ( 2017.1.1-2019.12.31, RMB190,000)
NSFC
7
Dr. Jin Liu
The role of osteoclastic miR-214-3p in subchondral bone remodeling during early osteoarthritis development (2018.1.1-2020.12.31, RMB200,000)
NSFC
8
Dr. Fangfei Li
Osteosarcoma-specific delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in a patient-derived xenograft model (2019.1.1-2021.6.30, HK$882,090)
GRF/RGC
9
Dr. Fangfei Li
Aptamer-based targeted delivery of CRISPR/Cas9 for therapeutic genome editing in osteosarcoma (2017.07-2019.06, RMB300,000)
Science and Technology Innovation Commission of Shenzhen Municipality
10
Dr. Fangfei Li
Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma ( 2018.01-2020.12, RMB200,000)
NSFC
Title